Asuragen launches new miRNA Biofluids service offering

March 04, 2016

Utilizing its cancerization field effect to identify molecular changes and enable detection of missed tumors, PCMT has demonstrated sensitivity of 84 percent and has also been shown to accurately rule out prostate cancer with a negative predictive value of 91 percent. PCMT uses existing prostate biopsy tissue, negating the need for an additional biopsy procedure, and it is performed quickly and easily on the previously obtained sample through a simple lab test.

"With the high rate of false negatives, uncertainty associated with traditional diagnostic tools, whether biochemical or histopathologic, and ongoing controversy regarding treatment paradigms, men at risk for prostate cancer are in need of new options," said Raoul Concepcion, M.D., F.A.C.S., director of clinical research, Urology Associates P.C. in Nashville, Tenn. "The ability of PCMT to use mtDNA to potentially identify malignancy by detecting underlying molecular alterations in normal-appearing tissue is an important advance for managing patients whom the urologist feels may be at increased risk."

Source: Mitomics